Droplet digital PCR measurement of HER2 in patients with gastric cancer

British Journal of Cancer

Volumn 112, Issue 10, 2015, Pages 1652-1655

  Kinugasa, H ^a   Nouso, K ^a   Tanaka, T ^a   Miyahara, K ^a   Morimoto, Y ^a   Dohi, C ^a   Matsubara, T ^b   Okada, H ^a   Yamamoto, K ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b OKAYAMA UNIVERSITY HOSPITAL   (Japan)

Author keywords

circulating DNA; circulating tumour DNA; ctDNA; Digital PCR; gastric cancer; HER2; liquid biopsy

Indexed keywords

CHLOROPLAST DNA; EPIDERMAL GROWTH FACTOR RECEPTOR 2; DNA; ERBB2 PROTEIN, HUMAN; PARAFFIN;

AGED; ARTICLE; CLINICAL ARTICLE; DROPLET DIGITAL POLYMERASE CHAIN REACTION; ENZYME BLOOD LEVEL; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOHISTOCHEMISTRY FLUORESCENCE IN SITU HYBRIDISATION; MALE; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; STOMACH CANCER; SURVIVAL TIME; ADULT; BLOOD; ENZYMOLOGY; GENETICS; MIDDLE AGED; PROCEDURES; STOMACH TUMOR; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; DNA; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MALE; MIDDLE AGED; PARAFFIN EMBEDDING; POLYMERASE CHAIN REACTION; RECEPTOR, ERBB-2; STOMACH NEOPLASMS;

EID: 84929291661     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2015.129     Document Type: Article

References (17)

1. Bang YJ, Van Cutsem E, Feyereislova A, Chung HC, Shen L, Sawaki A, Lordick F, Ohtsu A, Omuro Y, Satoh T, Aprile G, Kulikov E, Hill J, Lehle M, Ruschoff J, Kang YK. (2010). Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet 376(9742): 687-697
2. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, Scarffe JH, Lofts FJ, Falk SJ, Iveson TJ, Smith DB, Langley RE, Verma M, Weeden S, Chua YJ. (2006). Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355(1): 11-20
3. Dawson SJ, Tsui DW, Murtaza M, Biggs H, Rueda OM, Chin SF, Dunning MJ, Gale D, Forshew T, Mahler-Araujo B, Rajan S, Humphray S, Becq J, Halsall D, Wallis M, Bentley D, Caldas C, Rosenfeld N. (2013). Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med 368(13): 1199-1209
4. Gevensleben H, Garcia-Murillas I, Graeser MK, Schiavon G, Osin P, Parton M, Smith IE, Ashworth A, Turner NC. (2013). Noninvasive detection of HER2 amplification with plasma DNA digital PCR. Clin Cancer Res 19(12): 3276-3284
5. Gormally E, Caboux E, Vineis P, Hainaut P. (2007). Circulating free DNA in plasma or serum as biomarker of carcinogenesis: practical aspects and biological significance. Mutat Res 635(2-3): 105-117
6. Gravalos C, Jimeno A. (2008). HER2 in gastric cancer: a new prognostic factor and a novel therapeutic target. Ann Oncol 19(9): 1523-1529
7. Hindson BJ, Ness KD, Masquelier DA, Belgrader P, Heredia NJ, Makarewicz AJ, Bright IJ, Lucero MY, Hiddessen AL, Legler TC, Kitano TK, Hodel MR, Petersen JF, Wyatt PW, Steenblock ER, Shah PH, Bousse LJ, Troup CB, Mellen JC, Wittmann DK, Erndt NG, Cauley TH, Koehler RT, So AP, Dube S, Rose KA, Montesclaros L, Wang S, Stumbo DP, Hodges SP, Romine S, Milanovich FP, White HE, Regan JF, Karlin-Neumann GA, Hindson CM, Saxonov S, Colston BW. (2011). High-Throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem 83(22): 8604-8610
8. Hofmann M, Stoss O, Shi D, Buttner R, van de Vijver M, Kim W, Ochiai A, Ruschoff J, Henkel T. (2008). Assessment of a HER2 scoring system for gastric cancer: results from a validation study. Histopathology 52(7): 797-805
9. Kurokawa Y, Sugimoto N, Miwa H, Tsuda M, Nishina S, Okuda H, Imamura H, Gamoh M, Sakai D, Shimokawa T, Komatsu Y, Doki Y, Tsujinaka T, Furukawa H. (2014). Phase II study of trastuzumab in combination with S-1 plus cisplatin in HER2-positive gastric cancer (HERBIS-1). Br J Cancer 110(5): 1163-1168
10. Mason J, Griffiths M. (2012). Molecular diagnosis of leukemia. Expert Rev Mol Diagn 12(5): 511-526
11. Murtaza M, Dawson SJ, Tsui DW, Gale D, Forshew T, Piskorz AM, Parkinson C, Chin SF, Kingsbury Z, Wong AS, Marass F, Humphray S, Hadfield J, Bentley D, Chin TM, Brenton JD, Caldas C, Rosenfeld N. (2013). Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature 497(7447): 108-112
12. Ruschoff J, Hanna W, Bilous M, Hofmann M, Osamura RY, Penault-Llorca F, van de Vijver M, Viale G. (2012). HER2 testing in gastric cancer: a practical approach. Mod Pathol 25(5): 637-650
13. Sauter G, Lee J, Bartlett JM, Slamon DJ, Press MF. (2009). Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 27(8): 1323-1333
14. Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, Fleming T, Eiermann W, Wolter J, Pegram M, Baselga J, Norton L. (2001). Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 344(11): 783-792
15. Smith I, Procter M, Gelber RD, Guillaume S, Feyereislova A, Dowsett M, Goldhirsch A, Untch M, Mariani G, Baselga J, Kaufmann M, Cameron D, Bell R, Bergh J, Coleman R, Wardley A, Harbeck N, Lopez RI, Mallmann P, Gelmon K, Wilcken N, Wist E, Sanchez Rovira P, Piccart-Gebhart MJ (2007) 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 369(9555): 29-36
16. Tanner M, Hollmen M, Junttila TT, Kapanen AI, Tommola S, Soini Y, Helin H, Salo J, Joensuu H, Sihvo E, Elenius K, Isola J. (2005). Amplification of HER-2 in gastric carcinoma: association with Topoisomerase II alpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab. Ann Oncol 16(2): 273-278
17. Vogelstein B, Kinzler KW. (1999). Digital PCR. Proc Natl Acad Sci USA 96(16): 9236-9241